UBS lowered the firm’s price target on Avadel Pharmaceuticals (AVDL) to $14 from $22 and keeps a Buy rating on the shares. Avadel reported preliminary Q4 results and provided fiscal 2025 guidance, sending the stock down 30%, the analyst tells investors in a research note. The firm still believes that at current valuation, the stock is significantly cheap and can recover in the second half of 2025 as Lumryz growth starts to come back, but is now modeling peak Lumryz sales at $522M vs. its prior estimate of $565M.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVDL:
- UBS cuts Avadel target, says shares ‘significantly cheap’
- Venu Sports JV discontinued, Walgreens reports Q1 beat: Morning Buzz
- Oppenheimer cuts Avadel target, would buy on weakness
- Avadel Pharmaceuticals price target lowered to $17 from $23 at Craig-Hallum
- Piper Sandler cuts Avadel Pharmaceuticals price target, says staying bullish